Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
CyBorD + Daratumumab for Kidney Disease Related to Multiple Myeloma
Recruiting1 awardPhase 2
Uniondale, New York
This trial will determine if a combination of CyBorD and daratumumab is safe and effective for kidney disease related to multiple myeloma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service